Brokerages Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) PT at $61.38

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) have been assigned a consensus rating of “Buy” from the nine research firms that are presently covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $63.57.

Several equities analysts recently weighed in on CRBP shares. William Blair started coverage on Corbus Pharmaceuticals in a research report on Friday, February 28th. They set an “outperform” rating for the company. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Corbus Pharmaceuticals in a research report on Tuesday, February 18th. StockNews.com raised Corbus Pharmaceuticals to a “sell” rating in a research report on Thursday. Finally, Piper Sandler began coverage on Corbus Pharmaceuticals in a research report on Monday, December 2nd. They set an “overweight” rating and a $35.00 price objective for the company.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Several large investors have recently modified their holdings of CRBP. Vestcor Inc bought a new stake in shares of Corbus Pharmaceuticals in the 3rd quarter valued at approximately $64,000. Wells Fargo & Company MN grew its stake in shares of Corbus Pharmaceuticals by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 2,195 shares during the period. Avanza Fonder AB bought a new stake in shares of Corbus Pharmaceuticals in the 4th quarter valued at approximately $84,000. Deutsche Bank AG grew its stake in shares of Corbus Pharmaceuticals by 46.8% in the 4th quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 2,616 shares during the period. Finally, Aquatic Capital Management LLC bought a new stake in shares of Corbus Pharmaceuticals in the 4th quarter valued at approximately $101,000. 64.64% of the stock is currently owned by institutional investors.

Corbus Pharmaceuticals Price Performance

Shares of NASDAQ:CRBP opened at $6.97 on Tuesday. Corbus Pharmaceuticals has a fifty-two week low of $6.54 and a fifty-two week high of $61.90. The business has a 50-day moving average of $10.09 and a two-hundred day moving average of $21.18. The stock has a market capitalization of $84.89 million, a P/E ratio of -1.49 and a beta of 2.63.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.